Table 1 Cytotoxic effects of synthesized compounds against MCF-7, HT-29 and K562 cancer cell lines and vero non-cancer cells examined by MTT reduction assay expressed as IC50 values (µM)
From: Synthesis and cytotoxic activity evaluation of novel imidazopyridine carbohydrazide derivatives
Compound | Â | MCF-7A | HT-29 | K562 | Vero | miLog PB |
|---|---|---|---|---|---|---|
5 |
|  > 100C |  > 100 |  > 100 | –D | −0.08 |
9 |
| 70.1 ± 5.3 | 21.4 ± 1.9 | 23.7 ± 2.3 | 73.0 ± 9.9 | 0.65 |
7a |
|  > 100 |  > 100 |  > 100 | – | 2.70 |
7b |
|  > 100 |  > 100 |  > 100 | – | 2.86 |
7c |
| 64.8 ± 11.8 | 85.4 ± 10.3 |  > 100 | 65.6 ± 4.5 | 3.38 |
7d |
| 22.6 ± 1.0 | 13.4 ± 1.3 |  > 100 |  > 100 | 3.51 |
7e |
|  > 100 |  > 100 |  > 100 | – | 3.15 |
11a |
| 40.3 ± 2.9 | 61.2 ± 6.3 |  > 100 |  > 100 | 1.64 |
11b |
|  > 100 |  > 100 |  > 100 | – | 1.80 |
11c |
|  > 100 |  > 100 |  > 100 | – | 2.32 |
11d |
|  > 100 | 83.8 ± 13.1 |  > 100 |  > 100 | 2.00 |
11e |
|  > 100 |  > 100 |  > 100 | – | 2.09 |
Cisplatin | – | 25.9 ± 6.9 | 22.4 ± 5.8 | 9.4 ± 0.5 | 10.6 ± 1.3 |  |
Doxorubicin |  | 329.7E ± 130.8 | 750.3E ± 123.1 | 44.9E ± 2.4 | 2.6 ± 0.3 |  |
